Propylphenidine is a compound which has been sold as a designer drug, first identified in Australia in 2023. It is unclear what kind of activity it has, as it is claimed to be a stimulant in a patent along with related compounds such as phenylpropylaminopentane, but other structurally similar compounds such as ephenidine and isophenidine are dissociative anesthetic drugs, so it may produce either kind of activity or perhaps a mixture of both.[1][2][3]

Propylphenidine
Identifiers
  • N-(1,2-diphenylethyl)propan-1-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC17H21N
Molar mass239.362 g·mol−1
3D model (JSmol)
  • CCCNC(CC1=CC=CC=C1)C2=CC=CC=C2
  • InChI=1S/C17H21N/c1-2-13-18-17(16-11-7-4-8-12-16)14-15-9-5-3-6-10-15/h3-12,17-18H,2,13-14H2,1H3
  • Key:QDJKYFSVYJISOP-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ US 5220068, Knoll J, Simay A, Szinnyei E, Somfai E, Torok Z, Mozsolits K, Bergmann J, "Psychostimulant agent", issued 15 June 1993, assigned to Chinoin Private Co Ltd 
  2. ^ Morris H, Wallach J (July–August 2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–632. doi:10.1002/dta.1620. PMID 24678061.
  3. ^ Algar JL, Lawes DJ, Carroll AJ, Caldicott D, McLeod MD (January 2024). "Identification of three unexpected new psychoactive substances at an Australian drug checking service". Drug Testing and Analysis. doi:10.1002/dta.3637. PMID 38205685.